Astellas Pharma has ended a six-year-old collaboration with CytomX Therapeutics designed to both expand the pharma giant’s pipeline of next-gen immuno-oncology treatments and generate up to $1.68 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results